Details for New Drug Application (NDA): 040066
✉ Email this page to a colleague
NDA 040066 describes SULFACETAMIDE SODIUM, which is a drug marketed by Fougera Pharms, Padagis Us, Taro, Alcon Pharms Ltd, Bausch And Lomb, Epic Pharma Llc, Pharmafair, Sandoz, Sciegen Pharms Inc, and Genus, and is included in twelve NDAs. It is available from eleven suppliers. Additional details are available on the SULFACETAMIDE SODIUM profile page.
The generic ingredient in SULFACETAMIDE SODIUM is prednisolone sodium phosphate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate; sulfacetamide sodium profile page.
The generic ingredient in SULFACETAMIDE SODIUM is prednisolone sodium phosphate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate; sulfacetamide sodium profile page.
Summary for 040066
| Tradename: | SULFACETAMIDE SODIUM |
| Applicant: | Bausch And Lomb |
| Ingredient: | sulfacetamide sodium |
| Patents: | 0 |
Suppliers and Packaging for NDA: 040066
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SULFACETAMIDE SODIUM | sulfacetamide sodium | SOLUTION/DROPS;OPHTHALMIC | 040066 | ANDA | Bausch & Lomb Incorporated | 24208-670 | 24208-670-04 | 1 BOTTLE, DROPPER in 1 CARTON (24208-670-04) / 15 mL in 1 BOTTLE, DROPPER |
| SULFACETAMIDE SODIUM | sulfacetamide sodium | SOLUTION/DROPS;OPHTHALMIC | 040066 | ANDA | A-S Medication Solutions | 50090-0246 | 50090-0246-0 | 1 BOTTLE, DROPPER in 1 CARTON (50090-0246-0) / 15 mL in 1 BOTTLE, DROPPER |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 10% | ||||
| Approval Date: | Dec 28, 1994 | TE: | AT | RLD: | No | ||||
Complete Access Available with Subscription
